Drug intelligence / Profile preview

Buzhong Shechang Prescription

Development stage: Preclinical
Lead developer: Haihe
Administration: Oral

Overview

Buzhong Shechang Prescription is a Traditional Chinese Medicine (TCM) prescription currently under investigation for its efficacy and safety. It is being studied for the treatment of Low Anterior Resection Syndrome (LARS) which can occur after rectal cancer surgery. The drug is administered orally.

Other names: Buzhong Shibuchang prescription补中涩肠方

Beyond the preview

Go deeper on Buzhong Shechang Prescription.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Buzhong Shechang Prescription.

Explore the full profile